Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.60
FGEN's Cash-to-Debt is ranked lower than
69% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. FGEN: 2.60 )
Ranked among companies with meaningful Cash-to-Debt only.
FGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43  Med: 1.86 Max: 2.6
Current: 2.6
0.43
2.6
Equity-to-Asset 0.33
FGEN's Equity-to-Asset is ranked lower than
83% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. FGEN: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
FGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.33 Max: 0.46
Current: 0.33
-0.3
0.46
Piotroski F-Score: 5
Altman Z-Score: 2.18
Beneish M-Score: -3.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -29.88
FGEN's Operating Margin % is ranked higher than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. FGEN: -29.88 )
Ranked among companies with meaningful Operating Margin % only.
FGEN' s Operating Margin % Range Over the Past 10 Years
Min: -42.93  Med: -36.41 Max: -7.78
Current: -29.88
-42.93
-7.78
Net Margin % -34.35
FGEN's Net Margin % is ranked higher than
59% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. FGEN: -34.35 )
Ranked among companies with meaningful Net Margin % only.
FGEN' s Net Margin % Range Over the Past 10 Years
Min: -49.4  Med: -43.24 Max: -14.63
Current: -34.35
-49.4
-14.63
ROE % -35.79
FGEN's ROE % is ranked higher than
50% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. FGEN: -35.79 )
Ranked among companies with meaningful ROE % only.
FGEN' s ROE % Range Over the Past 10 Years
Min: -89.68  Med: -43 Max: -35.79
Current: -35.79
-89.68
-35.79
ROA % -13.02
FGEN's ROA % is ranked higher than
65% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. FGEN: -13.02 )
Ranked among companies with meaningful ROA % only.
FGEN' s ROA % Range Over the Past 10 Years
Min: -17.98  Med: -13.12 Max: -5.31
Current: -13.02
-17.98
-5.31
ROC (Joel Greenblatt) % -40.41
FGEN's ROC (Joel Greenblatt) % is ranked higher than
68% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. FGEN: -40.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -57.05  Med: -36.93 Max: -3.35
Current: -40.41
-57.05
-3.35
GuruFocus has detected 3 Warning Signs with FibroGen Inc $FGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FGEN Guru Trades in Q1 2016

Paul Tudor Jones 19,593 sh (New)
Joel Greenblatt Sold Out
» More
Q2 2016

FGEN Guru Trades in Q2 2016

Paul Tudor Jones 10,993 sh (-43.89%)
» More
Q3 2016

FGEN Guru Trades in Q3 2016

Jim Simons 223,300 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

FGEN Guru Trades in Q4 2016

Joel Greenblatt 21,899 sh (New)
Paul Tudor Jones 17,575 sh (New)
Jim Simons 332,600 sh (+48.95%)
» More
» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:HALO, OTCPK:MPSYY, NAS:ONCE, OTCPK:BVNRY, NAS:SRPT, NAS:DBVT, NAS:GBT, NAS:AAAP, OTCPK:VNAPF, NAS:ARRY, NAS:INVA, NAS:LXRX, NYSE:CBM, NYSE:AXON, NAS:BGNE, NAS:DERM, NAS:TBPH, NAS:PBYI, NAS:BPMC, OTCPK:ABCZF » details
Traded in other countries:1FG.Germany, FGEN.Mexico,
Headquarter Location:USA
FibroGen Inc is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.

FibroGen is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Top Ranked Articles about FibroGen Inc

FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Findings are Consistent with China Phase 3 Trials Results, and Support China NDA Submission

SAN FRANCISCO, March 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD) were published in the journal Nephrology Dialysis Transplantation. In these studies, in dialysis-dependent, and in non-dialysis-dependent CKD patients, roxadustat corrected and maintained hemoglobin levels regardless of the patients’ baseline iron repletion status, and levels of C-reactive protein (CRP), a marker of inflammation, consistent with what was seen in previously published results from the roxadustat global program. The publication, entitled “Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China,” is now available online at Nephrol Dial Transplant 2017 gfx011. doi: 10.1093/ndt/gfx011.
“Chronic kidney disease is a major chronic health condition in China, and anemia is one of CKD’s most common complications. The publication of this Phase 2 clinical data, along with recently reported Phase 3 primary endpoint data from trials conducted in China, show consistent findings of roxadustat’s potential to treat for dialysis and non-dialysis CKD patients,” said lead investigator Nan Chen, M.D., Department of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. “We are gratified to see this demonstration in China of the potential benefits of roxadustat, an oral anemia therapy.” “We are pleased with the positive data that we have seen from our China clinical development program for roxadustat. The published results from our Phase 2 program continue to show that that roxadustat corrects and maintains hemoglobin levels, maintain iron stores, and decreases levels of hepcidin,” said Chris Chung, FibroGen’s Vice President of China Operations. In the first study, 91 non-dialysis-dependent patients were dosed over eight weeks, according to two different weight-based dosing regimens. Hemoglobin levels were increased over baseline by more than 1.0 gm/dL in a significantly greater proportion of patients receiving roxadustat than patients receiving placebo (80% and 87.1% for the low- and high-dose roxadustat arms versus 23.3% in the placebo arm (p<0.0001, both)).In the second study, a conversion study in 87 dialysis-dependent CKD patients who had previously been treated for anemia, roxadustat was dosed according to one of three weight-based dosing regimens and compared with epoetin alfa. In this study, a higher proportion of the roxadustat-treated subjects − 59.1%, 88.9% (p=0.008), and 100% (p=0.0003), randomized to low, medium, and high doses of roxadustat, respectively − maintained their hemoglobin levels after five and six weeks of treatment, as compared to 50% of the epoetin alfa-treated subjects. Similar effects on iron metabolism were observed in each of the China Phase 2 studies, consistent with previously reported Phase 2 global trials. In particular, significant reductions in hepcidin levels were observed in roxadustat-treated subjects. Serum iron remained stable or increased in the roxadustat-treated arms, while total iron binding capacity (TIBC) and transferrin levels rose significantly. About CKD Anemia in China
Anemia commonly develops in association with chronic kidney disease (CKD) and is linked to significant morbidity and mortality in both the dialysis and non-dialysis populations. CKD affects an estimated 119.5 million patients in China (Zhang et al. Lancet 2012; 379: 815–822). Although CKD may occur at any age, it is more common in aging populations, and its prevalence is increasing. CKD can be both a cause and a consequence of cardiovascular disease and is a critical healthcare issue. Currently, there is no treatment available that is curative, or has the ability to stop kidney deterioration in patients with CKD with the exception of kidney transplantation.  The dialysis population in China, exceeding 400,000 patients, has been growing at a double-digit rate. The number of patients that require anemia therapy in China and other emerging markets is expected to increase steadily, as the CKD population continues to grow and the number of hemodialysis and peritoneal dialysis patients increases. We believe there is a significant opportunity for roxadustat to treat CKD anemia patients on dialysis (hemodialysis and peritoneal dialysis) and not on dialysis, as well as to address need in the large number of patients whose anemia remains undertreated or untreated in China. About Roxadustat
Roxadustat (FG-4592) is a first-in-class, orally administered small molecule currently in global Phase 3 clinical development as a potential therapy for anemia associated with chronic kidney disease (CKD). Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis – increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients – including in the presence of inflammation and without a need for supplemental intravenous iron.  Roxadustat is currently advancing through Phase 3 clinical trials worldwide, supported by extensive Phase 2 clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. To date, roxadustat has been evaluated in Phase 1 and Phase 2 studies, involving more than 1,400 subjects. Globally, a total of 15 Phase 3 studies, with target enrollment of about 10,000 patients worldwide, are currently being conducted to support independent regulatory approvals of roxadustat in both NDD-CKD and DD-CKD patients in the U.S., Europe, Japan, and China. Roxadustat is also entering a Phase 3 clinical trial in the U.S., and a Phase 2/3 clinical trial in China for the treatment of anemia in patients with myelodysplastic syndrome (MDS). For information about roxadustat trials currently recruiting patients, please visit www.clinicaltrials.gov.
About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase 3 development for anemia in myelodysplastic syndrome (MDS). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com. Forward-Looking Statements
This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the Company's product candidate, roxadustat, the potential safety and efficacy profile of roxadustat, the potential for regulatory submissions, and our clinical plans. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various non-clinical and clinical programs, including enrollment and conduct of our Phase 3 trials, the potential for Phase 2 results to be replicated or successful in larger Phase 3 trials, whether the results will support our planned NDA submission and the potential for approval in China, and our collaboration partners’ clinical trials for roxadustat in anemia associated with CKD, the continued progress of our plans and programs in China, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Contact
FibroGen, Inc.
Karen L. Bergman
VP, Investor Relations and Corporate Communications
1 (415) 978-1433
[email protected]

Read more...
FibroGen Reports Fiscal 2016 Financial Results

Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time

SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and provided an update on the company’s recent developments.
“We are pleased with the topline results reported from our two China Phase 3 trials, which are the first Phase 3 readouts for roxadustat, and bring us closer to completing our new drug application submission in China. With our partners AstraZeneca and Astellas, we are making steady progress in Phase 3 clinical development worldwide for roxadustat in CKD anemia, and continue to expect filing of our U.S. NDA in 2018,” said Thomas B. Neff, FibroGen’s Chief Executive Officer. “This year, we are expanding development activities for roxadustat into oncology-related anemias. We are also anticipating important clinical milestones for pamrevlumab, or FG-3019. We began the year with the presentation and publication of promising clinical results in pancreatic cancer, and expect to report data from our placebo-controlled Phase 2 trial in idiopathic pulmonary fibrosis in the third quarter of this year.” Recent Developments
U.S. and Europe Roxadustat (FG-4592) Anemia in Chronic Kidney Disease (CKD) Met initial target enrollment for three FibroGen-sponsored Phase 3 trials supporting U.S. and EU approvals and are continuing to enroll patients to meet overall enrollment goals among the partnersThe independent data safety monitoring board (DSMB), which reviews the U.S. and European Phase 3 program quarterly, recommended in February that trials continue without modification to current protocols China Roxadustat Anemia in Chronic Kidney Disease Completed the controlled portion of our two Phase 3 trials in 2016These studies met their primary endpoints for the treatment of anemia in non-dialysis and dialysis patients
-- In non-dialysis patients, roxadustat achieved a significantly greater increase in mean Hb and a significantly greater Hb response rate, as compared to patients in the placebo arm
-- In dialysis patients, roxadustat met the predefined non-inferiority criteria for the primary efficacy endpoint. In the pre-specified sequential analysis, roxadustat was also shown to be superior to 利血宝® (Li Xue Bao) epoetin alfa (Kirin EPO) in mean Hb increase Japan Roxadustat Anemia in Chronic Kidney Disease All six Phase 3 trials are now underwayPresented Phase 2 study results in non-dialysis-dependent patients in a clinical late-breaker session of the November 2016 American Society of Nephrology (ASN) Kidney Week U.S. Roxadustat Oncology-Related Anemias Phase 3 investigational new drug application was approved by the FDA for the treatment of anemia in myelodysplastic syndromes (MDS) in the fourth quarter of 2016 China Roxadustat Oncology-Related Anemias Submitted a clinical trial application (CTA), which is under review by the China Food and Drug Administration (CFDA), for a Phase 2/3 clinical study of anemia in MDS Pamrevlumab in Idiopathic Pulmonary Fibrosis (IPF) Completed enrollment of the Phase 2 double-blind, placebo-controlled -067 studyResults from Study -049 were published in the European Respiratory Journal, accompanied by an editorial, and the corresponding open-label extension results were presented at the 19th International Colloquium on Lung and Airway Fibrosis (ICLAF)
-- No safety issues reported with long-term treatment
-- Trend towards improved or stable pulmonary function and stable fibrosis continued in second year of treatment Pamrevlumab in Pancreatic Cancer Presented findings at the 2017 Gastrointestinal Cancers Symposium (ASCO-GI) from an ongoing open-label, randomized Phase 1/2 study in locally advanced pancreatic cancer -069 showing improvement in survival among patients in the combination arm, as compared to chemotherapy alonePublished Phase 1/2 trial results in the Journal of Cancer Clinical Trials reporting statistically significant dose-related increase in survival and that pamrevlumab can be safely combined with chemotherapy standard-of-care in advanced pancreatic cancer Corporate and Financial Highlights Net loss per basic and diluted share for the year ended December 31, 2016 was $0.98, as compared to $1.42 a year agoAt December 31, 2016, FibroGen had $342.2 million of cash, restricted time deposits, cash equivalents, investments, and receivables Outlook Report pamrevlumab topline Phase 2 IPF data, placebo-controlled and combination treatment sub-study results, in the third quarterSubmit new drug application in China in the third quarterExpect to complete enrollment of pamrevlumab open-label, randomized Phase 2 trial in locally advanced pancreatic cancer patients in the first half of the year, and to complete the patient treatment period by year-endOn track to submit the NDA for roxadustat in the U.S. in 2018 Conference Call Details
FibroGen will host a conference call and webcast today, March 1, 2017, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), to discuss financial results and provide a business update. Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. To access the conference call by telephone, please dial (888) 771-4371 (U.S. and Canada) or (847) 585-4405 (international), reference the FibroGen Year-End 2016 conference call, and use the confirmation number 44252209. It is recommended that listeners register 15 minutes before the scheduled start time to ensure a timely connection. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use the confirmation number 44252209#. About Roxadustat
Roxadustat (FG-4592) is a first-in-class, orally administered small molecule currently in global Phase 3 clinical development as a potential therapy for anemia associated with chronic kidney disease (CKD). Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis – increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients – including in the presence of inflammation and without a need for supplemental intravenous iron.  Roxadustat is currently advancing through Phase 3 clinical trials worldwide, supported by extensive Phase 2 clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. To date, roxadustat has been evaluated in Phase 1 and Phase 2 studies, involving more than 1,400 subjects. Globally, a total of 15 Phase 3 studies, with target enrollment of about 10,000 patients worldwide, are currently being conducted to support independent regulatory approvals of roxadustat in both NDD-CKD and DD-CKD patients in the U.S., Europe, Japan, and China. Roxadustat is also entering a Phase 3 clinical trial in the U.S. for treatment of anemia in patients with myelodysplastic syndrome (MDS). In China, a roxadustat MDS Phase 2/3 clinical trial application (CTA) is currently under review by the China Food and Drug Administration (CFDA). For information about roxadustat studies currently recruiting patients, please visit www.clinicaltrials.gov. About Pamrevlumab
Pamrevlumab (FG-3019) is an investigational therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. FibroGen is currently conducting clinical studies of pamrevlumab in idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy (DMD). In desmoplastic or fibrotic cancers, such as pancreatic cancer, CTGF in the extensive fibrous stroma associated with the tumor promotes abnormal proliferation of stromal cells and tumor cells. Studies in a transgenic mouse model of pancreatic cancer indicate that treatment with pamrevlumab in combination with chemotherapy may enhance the efficacy of chemotherapy and improve survival. For information about roxadustat studies currently recruiting patients, please visit www.clinicaltrials.gov.  About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com Forward-Looking Statements
This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the Company's product candidates, roxadustat and pamrevlumab, the potential safety and efficacy profile of our product candidates, the timelines for reporting of our clinical data reporting, potential milestones, and regulatory submissions, our clinical plans and our financial projections. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various non-clinical and clinical programs, including enrollment of our Phase 3 trials, and our collaboration partners’ clinical trials for roxadustat in anemia associated with CKD, the continued progress of our plans and programs in China, clinical development of and regulatory filing outcomes for anemia associated with myelodysplastic syndrome, the enrollment and results from ongoing clinical trials for pamrevlumab in IPF, and pancreatic cancer, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Condensed Consolidated Balance Sheets
(In thousands)    December 31, 2016  December 31, 2015  (Unaudited)  (1) Assets       Current assets:       Cash and cash equivalents$173,782  $153,324  Short-term investments 79,397   27,847  Accounts receivable 10,448   15,405  Prepaid expenses and other current assets 2,889   3,988  Total current assets 266,516   200,564          Restricted time deposits 6,217   7,254  Long-term investments 71,010   131,720  Property and equipment, net 123,657   129,020  Other assets 2,152   2,016  Total assets$469,552  $470,574          Liabilities, stockholders' equity and non-controlling interests       Current liabilities:       Accounts payable$6,223  $6,521  Accrued liabilities 50,914   47,932  Deferred revenue 7,988   12,728  Total current liabilities 65,125   67,181          Long-term portion of lease financing obligations 97,352   97,042  Product development obligations 14,854   15,085  Deferred rent 4,212   4,702  Deferred revenue, net of current 106,709   85,132  Other long-term liabilities 6,191   4,607  Total liabilities 294,443   273,749          Total stockholders’ equity 155,838   177,554  Non-controlling interests 19,271   19,271  Total equity 175,109   196,825  Total liabilities, stockholders' equity and non-controlling interests  $469,552  $470,574   (1) The condensed consolidated balance sheet amounts at December 31, 2015 are derived from audited financial statements.

Condensed Consolidated Statements of Operations
(In thousands, except per share data)   Years Ended December 31, 2016  2015 (Unaudited)
  (1)Revenue:      License and milestone revenue$137,352  $148,093 Collaboration services and other revenue 42,225   32,735 Total revenue 179,577   180,828 Operating expenses:      Research and development 187,206   214,089 General and administrative 46,025   44,364 Total operating expenses 233,231   258,453 Loss from operations (53,654)  (77,625)Interest and other, net:      Interest expense (10,725)  (11,033)Interest income and other, net 2,628   3,121 Total interest and other, net (8,097)  (7,912)Loss before income taxes (61,751)  (85,537)Provision for (benefit from) income taxes (71)  242 Net loss$(61,680) $(85,779)       Net loss per share - basic and diluted$(0.98) $(1.42)       Weighted average number of common shares used to calculate net loss per share - basic and diluted   62,744   59,926  (1) The condensed consolidated statements of operations amounts for the year ended December 31, 2015 are derived from audited financial statements.
Contact
FibroGen, Inc.
Karen L. Bergman
VP, Investor Relations and Corporate Communications
1 (415) 978-1433
[email protected]


Read more...

Ratios

vs
industry
vs
history
PB Ratio 11.42
FGEN's PB Ratio is ranked lower than
85% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. FGEN: 11.42 )
Ranked among companies with meaningful PB Ratio only.
FGEN' s PB Ratio Range Over the Past 10 Years
Min: 4.36  Med: 7.38 Max: 11.42
Current: 11.42
4.36
11.42
PS Ratio 10.24
FGEN's PS Ratio is ranked higher than
58% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. FGEN: 10.24 )
Ranked among companies with meaningful PS Ratio only.
FGEN' s PS Ratio Range Over the Past 10 Years
Min: 5.38  Med: 7.73 Max: 11.24
Current: 10.24
5.38
11.24
Price-to-Free-Cash-Flow 1037.03
FGEN's Price-to-Free-Cash-Flow is ranked lower than
98% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. FGEN: 1037.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
FGEN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 757.41  Med: 911.11 Max: 1037.03
Current: 1037.03
757.41
1037.03
Price-to-Operating-Cash-Flow 622.19
FGEN's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. FGEN: 622.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
FGEN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 454.44  Med: 546.67 Max: 622.19
Current: 622.19
454.44
622.19
EV-to-EBIT -30.73
FGEN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. FGEN: -30.73 )
Ranked among companies with meaningful EV-to-EBIT only.
FGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.73  Med: -19 Max: -8.8
Current: -30.73
-30.73
-8.8
EV-to-EBITDA -34.89
FGEN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. FGEN: -34.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
FGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.89  Med: -21.2 Max: -9.7
Current: -34.89
-34.89
-9.7
Current Ratio 4.09
FGEN's Current Ratio is ranked higher than
51% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. FGEN: 4.09 )
Ranked among companies with meaningful Current Ratio only.
FGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 3.16 Max: 4.09
Current: 4.09
2.23
4.09
Quick Ratio 4.09
FGEN's Quick Ratio is ranked higher than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. FGEN: 4.09 )
Ranked among companies with meaningful Quick Ratio only.
FGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.23  Med: 3.16 Max: 4.09
Current: 4.09
2.23
4.09
Days Sales Outstanding 21.24
FGEN's Days Sales Outstanding is ranked higher than
83% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. FGEN: 21.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
FGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.24  Med: 35.69 Max: 48.63
Current: 21.24
21.24
48.63

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 11.43
FGEN's Price-to-Tangible-Book is ranked lower than
79% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. FGEN: 11.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.29  Med: 8.74 Max: 11.43
Current: 11.43
7.29
11.43
Price-to-Median-PS-Value 1.32
FGEN's Price-to-Median-PS-Value is ranked lower than
62% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. FGEN: 1.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.01  Med: 1.04 Max: 1.43
Current: 1.32
1.01
1.43
Earnings Yield (Greenblatt) % -3.25
FGEN's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. FGEN: -3.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -276.72  Med: 0 Max: 0
Current: -3.25
-276.72
0

More Statistics

Revenue (TTM) (Mil) $179.6
EPS (TTM) $ -1.02
Short Percentage of Float2.91%
52-Week Range $14.50 - 27.30
Shares Outstanding (Mil)64.42

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 271 421
EPS ($) -0.89 0.34
EPS without NRI ($) -0.89 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for FGEN

Headlines

Articles On GuruFocus.com
FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock Apr 06 2017 
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadust Mar 31 2017 
Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of R Mar 30 2017 
FibroGen Reports Fiscal 2016 Financial Results Mar 01 2017 

More From Other Websites
Akebia expands anemia drug pact with Japanese firm, lifting shares Apr 25 2017
Akebia Expands Anemia Pill Partnership to Include Europe, China Rights Apr 25 2017
Why FibroGen Inc Popped Higher Today Apr 06 2017
Traders Are Focused on the Big-Caps Apr 06 2017
FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock Apr 06 2017
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : April 4, 2017 Apr 04 2017
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of... Mar 31 2017
Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of... Mar 30 2017
FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT Mar 02 2017
FibroGen Reports Fiscal 2016 Financial Results Mar 01 2017
FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017 Feb 22 2017
FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing... Feb 03 2017
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017 Jan 31 2017
Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen Jan 30 2017
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6% Jan 30 2017
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China Jan 30 2017
FibroGen (FGEN) Shares March Higher, Can It Continue? Jan 23 2017
Here Are Two Market Moving Biotech Catalysts To Watch This Week Jan 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)